Together, IL-13Rα2 and CD16 establish complementary recognition-activation circuitry within the TME: IL-13Rα2 confers tumor-specific binding, whereas CD16 triggers NK-cell cytotoxicity. This evidence concerns the gene IL13RA2 and neoplasm.